Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Clinical trial NCT06043973 · RECRUITING

Trial details

NCT number: NCT06043973
Sponsor: Qianfoshan Hospital
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Non-small Cell Lung Cancer

Start date: 2023-09-01
Primary completion: 2026-09-01
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.